REG - Oxford Biomedica PLC - Long Term Incentive Plan Option Grant

Oxford BioMedicaAnnouncement

21/03/2022 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220321:nRSU4453Fa&default-theme=true

RNS Number : 4453F  Oxford Biomedica PLC  21 March 2022

 

 

Long Term Incentive Plan Option Grant

 

London, UK - 21 March 2022: Oxford Biomedica plc ("Oxford Biomedica" or the
"Company") (LSE:OXB), a leading gene and cell therapy Group announces that on
18 March 2022 nil-cost share options over shares of 50 pence each in the
Company were granted under the Oxford Biomedica 2015 Long Term Incentive Plan
to Tim Kelly, Chief Executive Officer of Oxford Biomedica Solutions as part of
the arrangements agreed in connection with its deal with Homology.

 

Mr Kelly has been granted: a restricted stock award over 35,256 shares which
will vest in equal instalments on each of 10 March 2023, 10 March 2024, 10
March 2025 and 10 March 2026; a restricted stock award over 58,760 shares
which will vest as to 25% in September 2022, 25% in March 2023 and 50% in
September 2023; and a performance based award over 58,761 shares which will
vest following the end of a three year performance period subject to the
achievement of a revenue performance condition.

 

 Name of individual  Title                                                    Number of shares subject LTIP grant (restricted stock award)  Total shares over which options are held  Percentage of issued share capital under option
 Tim Kelly           Chief Executive Officer, Oxford of Biomedical Solutions  152,777                                                       152,777                                   0.16%

 

 

The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.

 

 

Notification of Dealing Form

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Tim Kelly
 2.  Reason for the notification
 a)  Position/status                          Chief Executive Officer of Oxford Biomedica Solutions

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Grant of awards over Ordinary Shares under the Company's Long Term Incentive
                                              Plan. No consideration was paid for the grant of awards.
 c)  Price(s) and volumes(s)                  Restricted stock award 1

Price(s)  Volume
                                              Nil       35,256

Restricted stock award 2

Price(s)  Volume
                                              Nil       58,760

Performance based award

Price(s)  Volume
                                              Nil       58,761

Restricted stock award 2

Price(s)  Volume
                                              Nil       58,760

Performance based award

Price(s)  Volume
                                              Nil       58,761
 d)  Aggregated information

     Aggregate volume                         Awards granted over 152,777 shares in total

     Price                                    N/A

 e)  Date of the transaction                  2022-03-18
 f)  Place of the transaction                 Outside of trading venue

Restricted stock award 2

 Price(s)  Volume
 Nil       58,760

Performance based award

 Price(s)  Volume
 Nil       58,761

d)

Aggregated information

Aggregate volume

 

Price

 

 

Awards granted over 152,777 shares in total

 

N/A

 

e)

Date of the transaction

2022-03-18

f)

Place of the transaction

Outside of trading venue

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group. In January 2022, Oxford Biomedica announced that it was
broadening its leading viral vector offerings by incorporating Homology
Medicines' established AAV capabilities into a newly formed AAV Manufacturing
and Innovation Business in the US with Homology Medicines as a 20% owner. To
date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector
leading lentiviral vector delivery platform (LentiVector®), which the Group
leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam
Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than 740 people.
Further information is available at www.oxb.com (http://www.oxb.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUPCWUPPGUG